President Trump has brokered a groundbreaking deal with pharmaceutical giants Eli Lilly and Novo Nordisk that will slash prices for some of America’s most expensive and widely-used medications, including the popular weight loss drugs Ozempic and Wegovy.
The landmark agreement, announced Thursday, will reduce the monthly cost of Ozempic and Wegovy from $1,000 and $1,350 respectively to just $350 through a new program called TrumpRx, according to White House officials. For Medicare beneficiaries, the prices will be even lower at $245 per month with a copay of only $50 — less than half the prices proposed by the Biden administration.
Beyond Weight Loss: A Broader Health Initiative
The deal extends far beyond just weight loss medications. Other discounted medicines will include Emgality for migraines at $299 per pen (saving patients $443), Trulicity for diabetes at $389 monthly (a $598 discount), and insulin products like NovoLog and Tresiba at $35 per month, the White House confirmed.
“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump said during the announcement. “When I say the price is different, you can see some examples where the price is beyond anything — four times, five times different.”
The administration’s move comes at a critical time. With the CDC estimating that 40% of American adults have obesity — a significant driver of chronic diseases including type 2 diabetes, heart disease, and certain cancers — access to these medications has become a pressing public health issue, White House officials noted.
Manufacturing Commitments and Economic Impact
Both pharmaceutical companies aren’t just lowering prices — they’re doubling down on American manufacturing. Novo Nordisk has committed an additional $10 billion investment to strengthen its domestic production capabilities, including plans to produce a Wegovy tablet entirely within the U.S. if approved. Under Trump’s leadership, Eli Lilly has announced at least $27 billion in new U.S. manufacturing investments, the White House stated.
What’s driving this sudden shift in pharmaceutical pricing? The answer lies in Trump’s May 12, 2025 Executive Order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” which directed the administration to align U.S. drug prices with the lowest prices paid in comparable OECD countries, as outlined in official documents.
This strategy addresses a longstanding disparity: despite having less than five percent of the world’s population, the U.S. has accounted for roughly 75% of global pharmaceutical profits, with Americans paying significantly higher prices than patients in other developed nations.
Looking Ahead: TrumpRx and Future Medications
The new TrumpRx platform, scheduled to launch in early 2026, will make nearly all primary care drugs from both companies available at U.S. net or Most Favored Nation prices. Perhaps most notably, the first oral GLP-1 drugs — the next generation of weight loss and diabetes medications that don’t require injection — will be priced at just $149 per month under the program, sources report.
The deals also set Most Favored Nation pricing for all future drug launches from Lilly and Novo Nordisk across commercial, Medicare, Medicaid, and cash markets. This follows the administration’s demand that manufacturers extend MFN pricing to every Medicaid patient, part of a broader push that has already resulted in five deals with major pharmaceutical manufacturers since September 30, 2025, as described by the White House.
For millions of Americans struggling with obesity, diabetes, and other chronic conditions, the announcement represents not just financial relief but potentially life-changing access to medications previously out of reach due to cost. Still, the full impact of these changes won’t be felt until the TrumpRx platform launches next year.
The healthcare industry will be watching closely to see if other pharmaceutical companies follow suit, potentially reshaping the landscape of prescription drug pricing in America for decades to come.
